Research progress in modern structure of platinum complexes

摘要

Abstract Since the antitumor activity of cisplatin was discovered in 1967 by Rosenberg, platinum-based anticancer drugs have played an important role in chemotherapy in clinic. Nevertheless, platinum anticancer drugs also have caused severe side effects and cross drug resistance which limited their applications. Therefore, a significant amount of efforts have been devoted to developing new platinum-based anticancer agents with equal or higher antitumor activity but lower toxicity. Until now, a large number of platinum-based complexes have been prepared and extensively investigated in?vitro and in?vivo . Among them, some platinum-based complexes revealing excellent anticancer activity showed the potential to be developed as novel type of anticancer agents. In this account, we present such platinum-based anticancer complexes which owning various types of ligands, such as, amine carrier ligands, leaving groups, reactive molecule, steric hindrance groups, non-covalently binding platinum (II) complexes, Platinum(IV) complexes and polynuclear platinum complexes. Overall, platinum-based anticancer complexes reported recently years upon modern structure are emphasized. Graphical abstract Display Omitted Highlights ? Platinum anticancer drugs have played an important role in clinic. ? Combination chemotherapy is a great way to develop new platinum-based drugs. ? The metallointercalators have greater cytotoxicity and smaller general toxicity. ? Platinum(IV) prodrugs could overcome the drawbacks of platinum(II) agents. ? Polynuclear platinum complexes with distinctive cytotoxic activities.